Ob/Gyn Medical News about Breast Neoplasms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK
PharmacoEconomics, 10/12/09

Benedict A et al. – In the base–case scenario, docetaxel compared with Pac3w is estimated to have a cost–effectiveness ratio that falls within the acceptable threshold in the UK. The study also suggests that docetaxel may be cost effective versus Pac1w and Nab–P, although there is more uncertainty around these findings.

<< Previous
A systematic review of treating Helicobacter pylori infection...

Next >>
Vulvar Mucinous Adenocarcinoma Associated with Crohn's Disease:...